Avelumab

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC) . Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma[1].

Product Specifications

CAS Number

[1537032-82-8]

Product Name Alternative

Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Avelumab.html

Purity

99.30

Solubility

H2O

Smiles

[Avelumab]

Molecular Weight

(150 kDa)

References & Citations

[1]Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016 Jun 7;7 (23) :33498-511.|[2]Grenga I, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016 May 20;5 (5) :e83.|[3]Vandeveer AJ, et al. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res. 2016 May;4 (5) :452-62.